Oxaliplatin (L-OHP) in combination with leucovorin and bolus-continuous infusion 5fluorouracil (LV5FU2) in advanced colorectal cancer (ACC) pretreated with 5FU

被引：1
|
作者：
Beretta, GD
Cascinu, S
Zaniboni, A
Ratti, R
Giordani, P
Catalano, V
Martignoni, G
Barni, S
Frontini, L
Labianca, R
机构：
[1] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[2] Univ Messina, Messina, Italy
[3] Casa Cura Poliambulanza, Brescia, Italy
[4] Casa Cura Igea, Milan, Italy
[5] Osped Muraglia, Pesaro, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)80689-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
256
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [41] Oxaliplatin (L-OHP) combined with continous infusion 5-fluorouracil (5-FU) and folinic acid (FA) based regimen in advanced colorectal cancer patients, confirmatory data on efficacy and toxicity
    Bochicchio, AM
    Capobianco, AML
    Coccaro, M
    Colasuonno, L
    Di Leo, P
    Galasso, R
    ANNALS OF ONCOLOGY, 2000, 11 : 64 - 64
  • [42] Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen):: A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer
    Ducreux, M
    Ychou, M
    Seitz, JF
    Bonnay, M
    Bexon, A
    Armand, JP
    Mahjoubi, M
    Méry-Mignard, D
    Rougier, P
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2901 - 2908
  • [43] Oxaliplatin, isovorin (IV) and 5-fluorouracil (5FU) as second-third line treatment in advanced colorectal carcinoma (ACC).
    de Castro, J
    Feliu, J
    Casado, E
    de Paredes, MLG
    Espinosa, E
    Zamora, P
    de las Heras, B
    Jiménez, A
    Ordóñez, A
    Barón, MG
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S74 - S74
  • [44] A randomised phase II study comparing irinotecan (IRI) plus leucovorin (LV) and 5-fluorouracil (5FU) versus IRI-LV-5FU followed be oxaliplatin (OXA) plus LV-5FU in patients with previously untreated metastatic colorectal cancer (CRC).
    Kalofonos, H. P.
    Papakostas, P.
    Aravantinos, G.
    Papadimitriou, C.
    Pentheroudakis, G.
    Varthalitis, I.
    Tsavdaridis, D.
    Syrigos, K.
    Kosmidis, P.
    Fountzilas, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 166S - 166S
  • [45] Palliative therapy for advanced biliary tract carcinoma with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV).
    Nehis, O
    Klump, B
    Gregor, M
    Porschen, R
    GASTROENTEROLOGY, 2000, 118 (04) : A523 - A523
  • [46] VNB and 5FU prolonged infusion in pretreated advanced breast cancer patients
    Tralongo, P
    Aiello, R
    Lavenia, G
    Paolello, C
    Salice, P
    Failla, G
    BREAST, 1997, 6 (05): : P909 - P909
  • [47] Bolus 5-fluorouracil plus leucovorin (FU-LV) in first-line treatment of advanced colorectal cancer.
    López, A
    Sánchez, J
    Gómez-Aldaraví, JL
    Fernández-Aramburo, A
    Yustos, A
    Romero, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S75 - S75
  • [48] Oxaliplatin and high dose 24 hours 5-fluorouracile (5FU) plus leucovorin (LV) as second line chemotherapy in advanced colorectal cancer.
    Nobile, MT
    Gozza, A
    Heouaine, A
    Chiara, S
    Murolo, M
    Cosso, M
    Lionetto, R
    Rosso, R
    ANNALS OF ONCOLOGY, 2000, 11 : 77 - 77
  • [49] Continuous infusion 5-fluorouracil (5FU) as a novel treatment for heavily pretreated prostate cancer patients: An update.
    Manogue, Charlotte
    Cotogno, Patrick
    Moses, Marcus Marie
    Barata, Pedro C.
    Layton, Jodi Lyn
    Sartor, A. Oliver
    Lewis, Brian E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [50] L-leucovorin (LLV) as a modulator of 5-days 5-fluorouracil (5FU) in advanced colorectal cancer (ACC): HIGH DOSE (HD) versus MW dose (LD)
    Labianca, R
    Cascinu, S
    Barni, S
    Fiorentini, G
    Frontini, L
    Comella, G
    Zaniboni, A
    Dallavalle, G
    Pancera, G
    Luporini, AC
    Pessi, A
    Luporini, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 735 - 735
12345